Cargando…
Pharmacovigilance for COVID-19 vaccines: A 1-year experience in France
As of February 2022, more than 130 million Covid vaccine doses had been distributed in France. During the first year of relevant vaccination, 128,766 adverse events (AE) were reported and analysed, as compared to an average of 40,000 per year for all drugs combined in the pre-pandemic years. A weekl...
Autores principales: | Crommelynck, S., Thill, P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Masson SAS.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492382/ https://www.ncbi.nlm.nih.gov/pubmed/36152793 http://dx.doi.org/10.1016/j.idnow.2022.09.018 |
Ejemplares similares
-
Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience
por: Oosterhuis, Ingrid, et al.
Publicado: (2022) -
Pharmacovigilance in vaccines
por: Budhiraja, Salil, et al.
Publicado: (2010) -
Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022) -
COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study
por: Ferrara, Francesco, et al.
Publicado: (2022) -
COVID-19 et vaccins à adénovirus : expérience française de suivi renforcé de pharmacovigilance
por: Massy, Nathalie, et al.
Publicado: (2023)